Author

Doris Ogresta

IMPACT OF SARS-COV-2 PANDEMIC ON IBD PATIENTS IN OUR TERTIARY CENTRE - CROSS SECTIONAL STUDY
IMPACT OF SARS-COV-2 PANDEMIC ON IBD PATIENTS IN OUR TERTIARY CENTRE - CROSS SECTIONAL STUDY

Doris Ogresta  et al.

HIGH EXPRESSION OF BROTHER OF THE REGULATOR OF THE IMPRINTED SITE (BORIS) CYTOPLASM-LOCALIZED PROTEIN IS NOT ASSOCIATED WITH HIGH-RISK FEATURES OF COLORECTAL CANCER
HIGH EXPRESSION OF BROTHER OF THE REGULATOR OF THE IMPRINTED SITE (BORIS) CYTOPLASM-LOCALIZED PROTEIN IS NOT ASSOCIATED WITH HIGH-RISK FEATURES OF COLORECTAL CANCER

Doris Ogresta  et al.

REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER
REAL-LIFE DATA OF TREATMENT PERSISTENCE IN PATIENTS WITH LONG-STANDING CROHN'S DISEASE TREATED WITH BIOLOGICS: RESULTS FROM A CROATIAN TERTIARY CENTER

Doris Ogresta  et al.

MAGE-A10 CANCER/TESTIS ANTIGEN IS HIGHLY EXPRESSED IN AGGRESSIVE SUB-TYPE OF COLORECTAL CANCER
MAGE-A10 CANCER/TESTIS ANTIGEN IS HIGHLY EXPRESSED IN AGGRESSIVE SUB-TYPE OF COLORECTAL CANCER

Doris Ogresta  et al.

LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY
LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY

Doris Ogresta  et al.

PERFORMANCE OF INTESTINAL ULTRASOUND SCORES IN DETECTING ACTIVE CROHN'S DISEASE
PERFORMANCE OF INTESTINAL ULTRASOUND SCORES IN DETECTING ACTIVE CROHN'S DISEASE

Doris Ogresta  et al.

UTILITY OF VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL IN PREDICTION OF BIO-NAIVE CROHN'S DISEASE PATIENTS OUTCOMES TREATED WITH ADALIMUMAB OR USTEKINUMAB
UTILITY OF VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL IN PREDICTION OF BIO-NAIVE CROHN'S DISEASE PATIENTS OUTCOMES TREATED WITH ADALIMUMAB OR USTEKINUMAB

Doris Ogresta  et al.

BIO-NAIVE CROHN'S DISEASE PATIENTS WITH LONG-STANDING DISEASE BENEFIT FROM USTEKINUMAB TREATMENT: REAL WORLD EXPERIENCE
BIO-NAIVE CROHN'S DISEASE PATIENTS WITH LONG-STANDING DISEASE BENEFIT FROM USTEKINUMAB TREATMENT: REAL WORLD EXPERIENCE

Doris Ogresta  et al.

ARTIFICIAL INTELLIGENCE IN HISTOPATHOLOGICAL DIAGNOSIS OF IBD – A PILOT STUDY
ARTIFICIAL INTELLIGENCE IN HISTOPATHOLOGICAL DIAGNOSIS OF IBD – A PILOT STUDY

Doris Ogresta  et al.

ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS
ELEVATED FECAL CALPROTECTIN IS GOOD INDICATOR OF PERSISTENT HISTOLOGICAL ACTIVITY DESPITE ENDOSCOPIC REMISSION IN UC PATIENTS TREATED WITH BIOLOGICS

Doris Ogresta  et al.

Item 1 - 10 / 10
1